Written questions by Osamor.

What assessment his Department has made of the potential impact of proposed changes to the GP contract in England on (a) minoritised ethnic groups and (b) those with less visible and chronic conditions.

The Department and NHS England assessed the potential impacts of the proposed changes to the GP Contract for 2026/27 throughout the policy-development process, including Equality Impact Assessments, which consider the impact of policy changes against protected characteristics, in line with the public sector equality duty. In relation to minoritised ethnic groups, the assessment found no evidence that the proposed changes would result in adverse impacts. The Department considers that several elements of the contract changes may support more equitable outcomes, including improvements to vaccination programmes and refinements to the Quality and Outcomes Framework (QOF), where uptake and disease prevalence are known to vary across different ethnic groups.In relation to people with less visible and chronic conditions, we do not anticipate any adverse impact from the changes. Measures to improve access, continuity of care, and proactive management of long‑term conditions are expected to benefit patients with ongoing and complex health needs. In particular, the introduction of continuity of care as a core requirement will require practices and primary care networks to use risk‑stratification tools more systematically to target continuity where it is most beneficial, supporting more consistent clinical relationships, and better outcomes. The updated QOF requirements for long term and chronic conditions such as diabetes, heart failure, and obesity, align indicators with updated National Institute for Health and Care Excellence guidance, and support earlier intervention and preventative care to improve clinical outcomes for patients. In addition, clarifying expectations around not asking patients to call back another day, and clinically urgent and non‑urgent requests, will support timely management of requests, reduce repeat contacts, and will help to avoid any patients being left without appropriate follow-up.The Department and NHS England will continue to monitor the impact of the GP Contract through workforce data, patient access metrics, and patient experience data, including demographic information collected through the GP Patient Survey, in order to identify and respond to any emerging differential impacts.

What plans are in place to ensure any changes to the National Institute for Health and Care Excellent (NICE) cost-effectiveness threshold are subject to parliamentary and public scrutiny.

The National Institute for Health and Care Excellence (NICE) has implemented a new cost-effectiveness threshold in its technology appraisals of £25,000 to £35,000 which is an increase from the previous threshold of £20,000 to £30,000. The new threshold is in line with the commitments made in the US-UK Economic Prosperity Deal announced in December 2025.The Government has engaged extensively with NICE, NHS England, the pharmaceutical industry and other parties throughout the process. The Government’s intended approach was set out in a Written Ministerial Statement on 13 April 2026, which is available at the following link:https://questions-statements.parliament.uk/written-statements/detail/2026-04-13/hlws1493In addition, my Rt. Hon. Friend, the Secretary of State for Health and Social Care, wrote to the chairs of the Health and Social Care Committee and the Science, Innovation and Technology Committee to inform them of the regulatory changes.

If he will publish an impact assessment of changes to the National Institute for Health and Care Excellent (NICE) cost-effectiveness threshold.

I refer the Hon. Member to the answer I gave to the Hon. Member for Oxford West and Abingdon on 4 March 2026 to question 114047.

What assessment he has made of the data management and privacy concerns of Palantir’s Federal Data Platform which were highlighted in the report from the health charity Medact, titled “Concerns Regarding Palantir Technologies and NHS Data Systems”.

Privacy by design is a core principle of the NHS Federated Data Platform (NHS FDP). NHS England constantly assesses privacy and data management through strict information governance processes detailed in the NHS Federated Data Platform Information Governance Framework. Data in the NHS FDP remains under National Health Service control at all times.Palantir does not control the data in the platform, nor are they permitted to access, use, or share it for their own purposes.The contract has strict stipulations about confidentiality, and there is governance in place to monitor delivery and usage. NHS England is the data controller of the national instance of the NHS FDP. Every hospital trust and integrated care board who has their own instance of the NHS FDP has complete control over who has access to their data platform.NHS England maintains continuous monitoring of the NHS FDP contract, to ensure it meets expectations. The NHS FDP is a major national digital infrastructure programme and is formally part of the Government’s Major Projects Portfolio (GMPP). The NHS FDP programme is subject to the scrutiny, assurance, and value for money standards required of all GMPP programmes. NHS FDP’s whole life costs and benefits are assessed through the annual GMPP process.The NHS FDP is subject to scrutiny by the National Infrastructure and Service Transformation Authority (NISTA) as part of the major projects review. NISTA’s latest data, published on 11 August 2025, sets out the projected benefits of NHS FDP at £777 million. The data records the Senior Responsible Owner Delivery Confidence rating as Green, the highest rating. The report is available at the following link:https://www.gov.uk/government/publications/nista-annual-report-2024-2025

What steps his Department is taking to support the provision of endometriosis services in Edmonton and Winchmore Hill constituency.

We are committed to improving the diagnosis, treatment, and ongoing care for gynaecological conditions including endometriosis, and we have already taken action to address this.Residents in Edmonton and Winchmore Hill have access to a well-established Enfield-wide community gynaecology and women’s health hub. The North Central London Integrated Care Board invests approximately £1 million per year in delivering this type of care in community settings across Enfield, including provision at the Winchmore Hill Practice itself. The service provides support across a range of gynaecological conditions, including endometriosis, and sees approximately 470 women each month. Care delivered through the community hub is increasingly integrated with both primary care and local acute services, helping women receive earlier assessment and support, with an average wait time of approximately four weeks, significantly shorter than typical hospital waiting times.Where women require more specialist investigation or treatment via a hospital, the North Middlesex University Hospital is currently the best performing acute site in North Central London for gynaecology services against the 18-week referral-to-treatment standard, with around 64% of women waiting less than 18 weeks. However, we recognise there is more to do and continue to work with providers to reduce waits as part of our wider elective recovery programme.Primary care is the key point of access for many women in Edmonton and Winchmore Hill, and we are supporting general practitioners (GPs) to access rapid specialist advice where endometriosis may be suspected. Local GPs can use Advice and Guidance services provided by experienced gynaecologists from local trusts and through a national network via a platform called Consultant Connect. This allows GPs to seek expert advice quickly, with 99% of responses received within five days, helping women receive appropriate support sooner and, where possible, closer to home.

What steps his Department is taking to improve education and training on endometriosis among healthcare professionals.

The Government acknowledges the challenges faced by women with endometriosis and the impact it has on their lives, their relationships, and their participation in education and the workforce.The Government also acknowledges the importance of ensuring healthcare professionals are adequately trained and educated on women’s health conditions, including endometriosis, and we have taken action to address this.The General Medical Council (GMC) has introduced the Medical Licensing Assessment to encourage a better understanding of common women’s health problems among all doctors as they start their careers in the United Kingdom. The content for this assessment includes several topics relating to women’s health, including endometriosis.Women's health is included the Royal College of General Practitioners (RCGP) curriculum for trainee general practitioners (GPs), including gynaecology, sexual health, and breast health. The curriculum also covers the healthcare needs of women across all diseases seen in primary care as it is important women are treated holistically. This ensures that all future GPs receive education on women’s health.The RCGP has also published a Women’s Health Library which brings together educational resources and guidelines on women’s health from the RCGP, the Royal College of Obstetricians and Gynaecologists, and the College of Sexual and Reproductive Healthcare. This resource is continually updated to ensure GPs and other primary healthcare professionals have the most up-to-date advice to provide the best care for their patients.The National Institute for Health and Care Excellence has developed a women’s and reproductive health topic suite, and updated guidelines on endometriosis in 2024 to make firmer recommendations for healthcare professionals on referral and investigations for women with suspected diagnosis. These clinical guidelines support healthcare professionals to provide care for women with endometriosis.Generally, employers in the health system are responsible for ensuring that their staff are trained to the required standards to deliver appropriate treatment for patients.

What funding provisions his Department has made in relation to the forthcoming National Tuberculosis Action Plan 2026–2031.

The Government is currently developing the Tuberculosis National Action Plan for 2026 to 2031. The content of the plan, including any associated funding requirements, has not yet been finalised. Any proposals with financial implications will be subject to the usual cross‑Government processes, including agreement with HM Treasury. Details, with funding commitments, will be included when the plan is published.

If he will make an assessment of the potential implications for his policies of Prostate Cancer Research's report entitled Prostate Cancer Screening: The Impact on the NHS, published in 14 October 2025.

The Government is guided by the independent, scientific advice of the UK National Screening Committee (UK NSC).The UK NSC Secretariat has corresponded with Prostate Cancer Research and described the committee’s formal published approach to identifying and summarising high quality, peer reviewed published evidence.The UK NSC Secretariat has read Prostate Cancer Research's report entitled Prostate Cancer Screening: The Impact on the NHS, and has discussed it with the Chair of the UK NSC.

What recent discussions he has had with trade unions on the (a) pay and (b) conditions of NHS support staff.

My rt. Hon. Friend, the Secretary of State for Health and Social Care, has had recent meetings with a number of general secretaries and health leads from trade unions representing staff on the Agenda for Change contract, including Unison, the Royal College of Nursing and GMB. Those meetings have focused on ways Government can continue to work with trade unions to improve working conditions for National Health Service staff, including NHS support staff, and how we can address concerns with pay within the current economic context.The Department regularly discusses workforce policy and staff experience matters for NHS support staff through the Social Partnership Forum, which is a national forum where NHS employers, trade unions, and the Department work together on issues that affect the NHS. In addition, the Department also engages with the NHS Staff Council, which has responsibility for maintaining the Agenda for Change system of pay and terms and conditions.

What steps his Department is taking to support (a) parents and (b) caregivers in making informed nutritional choices for children.

Children’s early years provide an important foundation for their future health and strongly influence many aspects of wellbeing in later life. The Government has published voluntary industry baby food guidelines as part of our comprehensive strategy to give children the best start in life. The guidelines challenge businesses to reduce the levels of salt and sugar in commercial baby food and drink products aimed at those aged up to 36 months. The guidelines also set out voluntary labelling actions for industry, in addition to reinforcing legislative requirements around labelling and health and nutrition claims. This will help to support parents and carers to make informed choices about what to feed their children. Businesses have 18 months from the publication of these guidelines, therefore by February 2027, to deliver the required changes. We will monitor industry progress towards implementing the sugar, salt, and labelling guidelines. It is vital that we maintain the highest standards for foods consumed by babies and infants, which is why we also have regulations in place that set nutritional, compositional, and labelling standards for commercial baby food. These ensure that commercial baby foods are suitable for infants and young children and require businesses to ensure labelling is clear and not misleading. The regulations also set labelling standards to ensure consumers have clear and accurate information about the products they buy. The Best Start in Life health website has advice for parents and carers on successful weaning of infants to introduce healthy solid foods, and is available at the following link: https://www.nhs.uk/start-for-life/ It has been updated to provide new advice on shop-bought baby food and healthy weaning practices. The update has been made in light of the increased availability and range of commercial baby food products, highlighting the need for clear and consistent advice for parents and carers. We continue to keep these regulations under review to ensure that the composition of infant food and drinks reflects the latest scientific advice and dietary guidelines. The voluntary industry baby food guidelines should support improvements in this area.

What assessment his Department has made of the potential impact of commercial baby foods being marketed for infants under six months on baby health.

Children’s early years provide an important foundation for their future health and strongly influence many aspects of wellbeing in later life. The Government has published voluntary industry baby food guidelines as part of our comprehensive strategy to give children the best start in life. The guidelines challenge businesses to reduce the levels of salt and sugar in commercial baby food and drink products aimed at those aged up to 36 months. The guidelines also set out voluntary labelling actions for industry, in addition to reinforcing legislative requirements around labelling and health and nutrition claims. This will help to support parents and carers to make informed choices about what to feed their children. Businesses have 18 months from the publication of these guidelines, therefore by February 2027, to deliver the required changes. We will monitor industry progress towards implementing the sugar, salt, and labelling guidelines. It is vital that we maintain the highest standards for foods consumed by babies and infants, which is why we also have regulations in place that set nutritional, compositional, and labelling standards for commercial baby food. These ensure that commercial baby foods are suitable for infants and young children and require businesses to ensure labelling is clear and not misleading. The regulations also set labelling standards to ensure consumers have clear and accurate information about the products they buy. The Best Start in Life health website has advice for parents and carers on successful weaning of infants to introduce healthy solid foods, and is available at the following link: https://www.nhs.uk/start-for-life/ It has been updated to provide new advice on shop-bought baby food and healthy weaning practices. The update has been made in light of the increased availability and range of commercial baby food products, highlighting the need for clear and consistent advice for parents and carers. We continue to keep these regulations under review to ensure that the composition of infant food and drinks reflects the latest scientific advice and dietary guidelines. The voluntary industry baby food guidelines should support improvements in this area.

What steps his Department is taking to reduce levels of sugar in snacks for children under two.

Children’s early years provide an important foundation for their future health and strongly influence many aspects of wellbeing in later life. The Government has published voluntary industry baby food guidelines as part of our comprehensive strategy to give children the best start in life. The guidelines challenge businesses to reduce the levels of salt and sugar in commercial baby food and drink products aimed at those aged up to 36 months. The guidelines also set out voluntary labelling actions for industry, in addition to reinforcing legislative requirements around labelling and health and nutrition claims. This will help to support parents and carers to make informed choices about what to feed their children. Businesses have 18 months from the publication of these guidelines, therefore by February 2027, to deliver the required changes. We will monitor industry progress towards implementing the sugar, salt, and labelling guidelines. It is vital that we maintain the highest standards for foods consumed by babies and infants, which is why we also have regulations in place that set nutritional, compositional, and labelling standards for commercial baby food. These ensure that commercial baby foods are suitable for infants and young children and require businesses to ensure labelling is clear and not misleading. The regulations also set labelling standards to ensure consumers have clear and accurate information about the products they buy. The Best Start in Life health website has advice for parents and carers on successful weaning of infants to introduce healthy solid foods, and is available at the following link: https://www.nhs.uk/start-for-life/ It has been updated to provide new advice on shop-bought baby food and healthy weaning practices. The update has been made in light of the increased availability and range of commercial baby food products, highlighting the need for clear and consistent advice for parents and carers. We continue to keep these regulations under review to ensure that the composition of infant food and drinks reflects the latest scientific advice and dietary guidelines. The voluntary industry baby food guidelines should support improvements in this area.

What assessment his Department has made of the potential impact of (a) cartoon characters on baby food packaging and (b) other child-directed imagery on baby health.

Children’s early years provide an important foundation for their future health and strongly influence many aspects of wellbeing in later life. The Government has published voluntary industry baby food guidelines as part of our comprehensive strategy to give children the best start in life. The guidelines challenge businesses to reduce the levels of salt and sugar in commercial baby food and drink products aimed at those aged up to 36 months. The guidelines also set out voluntary labelling actions for industry, in addition to reinforcing legislative requirements around labelling and health and nutrition claims. This will help to support parents and carers to make informed choices about what to feed their children. Businesses have 18 months from the publication of these guidelines, therefore by February 2027, to deliver the required changes. We will monitor industry progress towards implementing the sugar, salt, and labelling guidelines. It is vital that we maintain the highest standards for foods consumed by babies and infants, which is why we also have regulations in place that set nutritional, compositional, and labelling standards for commercial baby food. These ensure that commercial baby foods are suitable for infants and young children and require businesses to ensure labelling is clear and not misleading. The regulations also set labelling standards to ensure consumers have clear and accurate information about the products they buy. The Best Start in Life health website has advice for parents and carers on successful weaning of infants to introduce healthy solid foods, and is available at the following link: https://www.nhs.uk/start-for-life/ It has been updated to provide new advice on shop-bought baby food and healthy weaning practices. The update has been made in light of the increased availability and range of commercial baby food products, highlighting the need for clear and consistent advice for parents and carers. We continue to keep these regulations under review to ensure that the composition of infant food and drinks reflects the latest scientific advice and dietary guidelines. The voluntary industry baby food guidelines should support improvements in this area.

What assessment he has made of the potential merits of including specialist dementia nurses as part of the Neighbourhood Health Service.

The Neighbourhood Health Service will bring together teams of professionals, closer to people’s homes, to work together to provide comprehensive care in the community. We expect neighbourhood teams and services to be designed in a way that reflects the specific needs of local populations, and so they could include dementia nurses. While we will be clear on the outcomes we expect, we will give significant licence to tailor the approach to local need. While the focus on personalised, coordinated care will be consistent, services may look different in rural communities, coastal towns, and deprived inner cities, depending on local need.

What steps he is taking to help improve the availability of tuberculosis medication.

Medicine supply chains are complex, global, and highly regulated, and there are a number of reasons why supply can be disrupted, many of which are not specific to the United Kingdom and are outside of Government control, including manufacturing difficulties, access to raw materials, sudden demand spikes or distribution issues, and regulatory issues. There are approximately 14,000 licensed medicines and the overwhelming majority are in good supply. Where there are supply issues, these are managed at a national level across the UK rather than at a regional level.NHS England has been notified of some issues with medicines used to treat tuberculosis (TB), however there is sufficient stock available from alternative suppliers to meet normal demand for most of them. The products facing current disruptions include Voractiv tablets until late June 2025, and rifampicin 150 milligram capsules until mid-August 2025, both due to manufacturing delays. Comprehensive management plans were communicated to healthcare professionals on 1 June 2025, highlighting issues with TB medicines and advising of the actions to take during this time. NHS England is actively working with the affected suppliers to address these supply issues as quickly as possible to ensure that UK patients have access to the medications they need.The team are working intensively to improve the availability of TB medicines, which includes co-ordinating with the British Thoracic Society to ensure centres treating active TB have access to available supplies, and directing trusts to build buffer stocks of unlicensed imports of TB medicines whilst there is a supply issue with some UK licensed products. The team are also supporting the impacted supplier and trusts to ensure that the available TB medicine supplies are equitably distributed and allocated fairly across the UK. The team is continuing to explore medium to long term solutions to the supply issues, working with those mentioned as well as the Medicines and Healthcare products Regulatory Agency and clinicians within the NHS.

What assessment he has made of the potential impact of the availability of tuberculosis medication on the provision of healthcare in London.

Medicine supply chains are complex, global, and highly regulated, and there are a number of reasons why supply can be disrupted, many of which are not specific to the United Kingdom and are outside of Government control, including manufacturing difficulties, access to raw materials, sudden demand spikes or distribution issues, and regulatory issues. There are approximately 14,000 licensed medicines and the overwhelming majority are in good supply. Where there are supply issues, these are managed at a national level across the UK rather than at a regional level.NHS England has been notified of some issues with medicines used to treat tuberculosis (TB), however there is sufficient stock available from alternative suppliers to meet normal demand for most of them. The products facing current disruptions include Voractiv tablets until late June 2025, and rifampicin 150 milligram capsules until mid-August 2025, both due to manufacturing delays. Comprehensive management plans were communicated to healthcare professionals on 1 June 2025, highlighting issues with TB medicines and advising of the actions to take during this time. NHS England is actively working with the affected suppliers to address these supply issues as quickly as possible to ensure that UK patients have access to the medications they need.The team are working intensively to improve the availability of TB medicines, which includes co-ordinating with the British Thoracic Society to ensure centres treating active TB have access to available supplies, and directing trusts to build buffer stocks of unlicensed imports of TB medicines whilst there is a supply issue with some UK licensed products. The team are also supporting the impacted supplier and trusts to ensure that the available TB medicine supplies are equitably distributed and allocated fairly across the UK. The team is continuing to explore medium to long term solutions to the supply issues, working with those mentioned as well as the Medicines and Healthcare products Regulatory Agency and clinicians within the NHS.

What steps his Department is taking to increase public awareness of the role of naloxone in preventing opioid-related deaths.

The Government has amended the Human Medicines Regulations 2012 to expand access to naloxone. The legislation means more services and professionals can supply this medication without prescription, which in turn means easier access to it for people at risk, and for their loved ones. The Department has recently published guidance that sets out essential practical information such as who can supply naloxone, the products available, how to use naloxone and other basic lifesaving tools, and the training required. Additionally, guidance is also available for local areas to prepare for potent synthetic opioid incidents and to strengthen their preparedness.Local authorities are responsible for commissioning drug treatment services as part of their public health responsibilities, and they provide funding for naloxone supplied through drug treatment services based on their assessment of local need. In addition to the Public Health Grant, in 2025/26 the Department is providing a total of £310 million in additional targeted grants to improve drug and alcohol services and recovery support, including naloxone provision.Raising awareness of naloxone and its lifesaving potential amongst the general public is important. The Government has a drug and alcohol information and advice service called Talk to FRANK which aims to reduce drug and alcohol use and their harms by providing information and increasing awareness for young people, parents, and concerned others. This website has a page providing detailed information on when and how to use naloxone, which is available at the following link:https://www.talktofrank.com/get-help/what-to-do-in-an-emergencyDepartment of Health and Social Care and Home Office ministers have written to festival organisers, asking them to work closely with police and health partners on their harm reduction and first aid measures, which includes ensuring that naloxone is readily available. The Department has also worked with the National Police Chiefs’ Council on a joint letter and advice for the police and local authorities about festivals, drugs, and alcohol, to minimise the risk of harm to individuals at these events. The advice highlights that naloxone remains an effective, life-saving tool in the face of a synthetic opioid overdose.

What steps he is taking to reduce competition ratios for specialty training for doctors.

We are committed to training the staff we need to ensure patients are cared for by the right professional, when and where they need it.We will ensure that the number of medical specialty training places meets the demands of the National Health Service in the future. NHS England will work with stakeholders to ensure that any growth is sustainable and focused in the service areas where need is greatest.To reform the NHS and make it fit for the future, we have launched a 10-Year Health Plan as part of Government’s five long-term missions. Ensuring we have the right people, in the right places, with the right skills will be central to this vision. We will publish a refreshed Long Term Workforce Plan to deliver the transformed health service we will build over the next decade, and treat patients on time again.

What steps he is taking to improve tuberculosis (a) screening, (b) diagnosis and (c) treatment services for (i) people experiencing homelessness and (ii) asylum seekers.

The Department works collaboratively with Government departments, local authorities, and third-sector organisations to overcome barriers to healthcare access for people seeking asylum and those experiencing homelessness, ensuring they can access and receive necessary care.The UK Health Security Agency (UKHSA) collects and publishes data on tuberculosis (TB). The UKHSA and NHS England’s joint TB Action Plan for England 2021 to 2026 outlines outcomes and indicators to achieve a 90% reduction in people with TB by 2035, which is aligned with the World Health Organization’s elimination targets.There are specific actions within the collaborative UKHSA and NHS England TB Action Plan 2021 to 2026 to strengthen the prevention and detection of active disease in groups at higher risk of TB, such as those experiencing homelessness and seeking asylum, through targeted screening and active engagement with local authorities, their public health teams, and the third sector.

Whether he is taking steps to increase the number of entry-level positions for newly qualified physiotherapists.

Decisions about the employment of newly qualified physiotherapists are a matter for individual National Health Service trusts. NHS trusts manage their recruitment at a local level, ensuring they have the right number of staff in place, with the right skill mix, to deliver safe and effective care.We will publish a refreshed Long Term Workforce Plan to deliver the transformed health service we will build over the next decade, and treat patients on time again.